| PRECLINICAL | evidence | Data-driven prioritization of high-risk individuals for weight loss interventions. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Weight-loss dynamics with tirzepatide versus semaglutide. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Facial nodules following filler injections after initiating compounded tirzepatide use. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Tirzepatide-associated interstitial kidney injury. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Nutrition Strategies for Next-Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists Improve Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction, Independent of Diabetes: A Systematic Review and Meta-Analysis. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Evaluating the Efficacy of Sodium Glucose Cotransporter-2 Inhibitors in Management of Obstructive Sleep Apnea; a Systematic Review and Meta-Analysis. | Zepbound | Sleep quality · n = 686 | 2026-06-01 |
| PRECLINICAL | evidence | Acute Small Bowel Obstruction Induced by Tirzepatide (Mounjaro). | Mounjaro | — | 2026-06-01 |
| PRECLINICAL | evidence | Anterior Cutaneous Nerve Entrapment Syndrome From Glucagon-Like Peptide-1 Receptor Agonist Injection. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications: A Multicenter US Cohort Study. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists as a metabolic optimization strategy in surgical prehabilitation: a translational perspective. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Disparities in Adolescent and Young Adult Obesity Medication Dispensing: A Retrospective Linked EHR-Pharmacy Cohort, 2020-2025. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Impact of Tirzepatide Therapy on Thyroid Disease: Understanding Risks and Emerging Insights. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes. | Tirzepatide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Marked improvement in severe hidradenitis suppurativa following tirzepatide therapy: a case report. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review. | Tirzepatide | Liver health | 2026-06-01 |
| PRECLINICAL | evidence | Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Dual GIPR and GLP-1R Agonist Tirzepatide Is Associated With Fewer Asthma Exacerbations in Adults With Obesity. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Comment on Sattar et al. Weight Reduction With Tirzepatide Varied Meaningfully by Baseline HbA1c Category in Adults With Overweight or Obesity and Type 2 Diabetes in SURMOUNT-2. Diabetes Care 2025;48:e136-e137. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Impact of GLP-1 and GLP-1/GIP agonists on healthcare resource utilization in individuals with scarring alopecias: A retrospective cohort analysis using TriNetX. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Cellulite as a Possible Biomarker of Metabolic Dysfunction: Redefining Body Remodeling in the Glucagon-Like Peptide-1 Era Through the Cellulite Removal Medical Protocol-G21 Concept. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Tirzepatide: A turning point in obesity related heart failure with preserved ejection fraction? | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | ICER report demonstrates both the value and challenges in financing of weight loss medications. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Beyond superiority: preserved cardiovascular efficacy and emerging signals in SURPASS-CVOT. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | The efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies. | Tirzepatide | Inflammation | 2026-06-01 |
| PRECLINICAL | evidence | Tirzepatide in obese patients with psoriasis on biological therapy: Is this a window of opportunity? | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes. | Tirzepatide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis. | Tirzepatide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions-A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data. | Tirzepatide | — | 2026-05-31 |
| PRECLINICAL | evidence | The impact of adjuvant anti-obesity medications on 10-year weight loss outcomes after sleeve gastrectomy. | Tirzepatide | — | 2026-05-30 |
| PRECLINICAL | evidence | Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance. | Tirzepatide | Weight & fat loss | 2026-05-29 |
| PRECLINICAL | evidence | Akkermansia muciniphila and GLP-1-Based Therapies: Bidirectional Interactions and Implications for Type 2 Diabetes and MASLD/MASH. | Tirzepatide | — | 2026-05-29 |
| PRECLINICAL | evidence | Shrinking appetites: Will GLP-1 adoption in high-income countries accelerate Big Food's push into low- and middle-income countries? | Zepbound | — | 2026-05-28 |
| PRECLINICAL | evidence | After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care. | Tirzepatide | Weight & fat loss | 2026-05-28 |
| PRECLINICAL | evidence | Maintaining weight loss with tirzepatide . . . and other research. | Tirzepatide | — | 2026-05-28 |
| PRECLINICAL | evidence | Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis. | Tirzepatide | — | 2026-05-28 |
| PRECLINICAL | evidence | Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database. | Tirzepatide | — | 2026-05-28 |